Ruterlin, Valen
Unknown Affiliation

Published : 2 Documents
Articles

Found 2 Documents
Search

Pengaruh Pengobatan ARV terhadap Peningkatan Limfosit Pasien HIV-AIDS di Rumah Sakit Pemerintah Kota Palu Ruterlin, Valen; Tandi, Joni
Indonesian Journal of Clinical Pharmacy Vol 3, No 1 (2014)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (745.423 KB) | DOI: 10.15416/ijcp.2014.3.1.30

Abstract

 Berdasarkan laporan unit rekam medik sebuah rumah sakit pemerintah di Kota Palu periode Januari?Agustus 2010 terdapat 12 pasien yang didiagnosis sebagai positif HIV-AIDS. Etiologi penyakit ini ditandai dengan berat badan menurun, diare kronik yang berlangsung lebih dari 1 bulan, demam berkepanjangan lebih dari 1 bulan, infeksi saluran pernapasan bagian bawah yang parah atau menetap. HIV-AIDS merupakan penyakit yang disebabkan oleh retrovirus yang menyerang sel darah putih (limfosit) sehingga menurunkan sistem kekebalan tubuh. Penelitian ini bertujuan untuk mengetahui pengaruh pengobatan antiretroviral (ARV) pada peningkatan limfosit di rumah sakit pemerintah Kota Palu. Metode pengumpulan data dilakukan secara retrospektif pada Januari?Juni 2013 dan analisis hasil data menggunakan metode deskriptif nonparametik. Hasil penelitian menunjukkan terdapat peningkatan yang signifikan terhadap limfosit dengan kombinasi obat staviral (NRTI), efavirenz (NNRTI), dan duviral (NRTI), hiviral (NRTI), neviral (NNRTI) pada pasien awat jalan yang positif HIV-AIDS. Dengan demikian dapat disimpulkan bahwa pemberian ARV berpengaruh pada peningkatan limfosit sehingga akan meningkatkan sistem kekebalan tubuh pasien HIV-AIDS.Kata kunci: Antiretroviral (ARV), HIV-AIDS, sel limfositMedicational Influence of ARV with Increasing Limfosit of HIV-AIDS?s Patient at Public Hospital in PaluBased on medical records of a public hospital in Palu period January to August 2010, there were 12 patients who diagnosed HIV-AIDS positive. The etiology of the disease is characterized by weight loss, chronic diarrhea more than one month, fever more than one month, lower respiratory tract infections are severe or persistence. HIV-AIDS is a disease caused by a retrovirus that attacks white blood cells (lymphocytes), which decreasing the immune system. The aim of this study was to determine the effect of antiretroviral treatment (ARV) with increasing lymphocytes at a public hospital in Palu. Data were collected and retrospective analysis were conducted using a nonparametik descriptive method during January?Juny 2013. The results showed that there was a significant increasing on the white blood cells lymphocytes) with a combination of drugs staviral (NRTIs), efavirenz (NNRTI), and combivir (NRTIs), hiviral (NRTIs), neviral (NNRTIs) in outpatient with HIV-AIDS positive. It can be concluded that theeffect on the increase in ARV lymphocytes will increase the immune system of patients with HIV-AIDS.Key words: Antiretroviral (ARV), HIV-AIDS, limphocyte cells
Economic Evaluation of the Use of Cefotaxime and Ceftazidime in the Treatment of Pneumonia in Pediatric Patients Ruterlin, Valen; Sinuraya, Rano K.; Halimah, Eli; Barliana, Melisa I.; Hartini, Sri
Pharmacology and Clinical Pharmacy Research Vol 2, No 1
Publisher : Universitas Padjadjaran, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (229.785 KB) | DOI: 10.15416/pcpr.v2i1.15741

Abstract

The prevalence of pneumonia is particularly high among pediatric patients. Appropriate antibioticsselection is required to reduce mortality and morbidity rates associated with thesediseases. However, information on cost-effectiveness of empirical antibiotics treatment forpneumonia was limited. This study was aimed to evaluate cost-effectiveness of cefotaximeand ceftazidime for pneumonia in pediatric patients. This study was a retrospective crosssectional study conducted at a hospital in Bandung during January-December 2012. Datawere derived from medical records of pediatric pneumonia inpatients during study period.Cost was calculated based on direct medical cost, i.e., inpatient care, medical support, andmedicines that were used from admission until hospital discharge. The results showed thatthere was no statistical difference in the average medical cost of the treatment using cefotaxime(1,197,017 IDR) and ceftazidime (2,245,748 IDR). Incremental cost effectivenessratio (ICER) showed that cefotaxime is more cost effective than ceftazidime with greaterreduction of leukocytes level (576 IDR/mm3 ). The use of cefotaxime is recommended forthe treatment of pnuemonia in pediatric patients.Keywords: cost minimization, cost effectiveness, cefotaxime, ceftazidime, pneumonia